Application of dyclonine hydrochloride in prevention of hypothalamic-pituitary-ovarian axis injury of female mouse

Through dacroin hydrochloride inhibition of RA signaling pathway and NF-kB inflammation pathway, the damage problem of environmental pollutants Cd2+ and Pythorid on the hypothalamus-pituitary-ovarian axis is solved, and the fertility function protection of female mice is achieved and Recovery of reproductive capacity.

CN119074731AActive Publication Date: 2024-12-06HUNAN NORMAL UNIVERSITY
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
CN202411316488.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-20
Publication Date
2024-12-06
Estimated Expiration
2044-09-20

AI Technical Summary

Technical Problem

Environmental pollutants Cd2+ and Pythoridine cause damage to the hypothalamic-pituitary-ovarian axis, affecting estrogen function and reproductive function, and it is difficult to effectively prevent and treat the existing technology.

Method used

Dacroin hydrochloride is used as a small molecule drug, and pH value is adjusted to neutral through intraperitoneal injection, inhibiting the RA signaling pathway and NF-kB inflammatory pathway, and protecting the hypothalamus-pituitary-ovarian axis.

Benefits of technology

Effectively prevent and treat hypothalamic-pituitary-ovarian axis damage, restore or improve reproductive ability, and significantly protect the fertility function of female mice.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074731A_ABST
    Figure CN119074731A_ABST
Patent Text Reader

Abstract

The invention relates to the field of biological medicine, in particular to application of dyclonine hydrochloride in prevention of hypothalamic-pituitary-ovarian axis injury of female mice. The invention discloses a potential mechanism that low-level Cd < 2 + > and procymidone are combined to damage the hypothalamus-pituitary-ovarian axis of a mouse, and provides a small-molecule drug-dyclonine hydrochloride for preventing damage based on the mechanism, and a preparation method of the small-molecule drug comprises the following steps: dissolving dyclonine hydrochloride in a phosphate buffer solution, and then adjusting the pH value to be about 7.4. The concentration for intraperitoneal injection is 10 mg / kg.bw / d. The preparation method of the small molecule medicine is simple, the RA signal channel and the NF-kB inflammation channel can be effectively inhibited, the safety is high, and the hypothalamic-pituitary-ovarian axis of a female mouse can be effectively protected.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to a drug for preventing and treating environmental endocrine disruptors from damaging the hypothalamus-pituitary-ovarian axis, in particular based on low-level Cd 2+ A preventive and therapeutic drug developed in combination with fosetyl-Al that damages the hypothalamic-pituitary-ovarian axis in female mice. Background Art

[0002] The Hypothalamus-Pituitary-Ovary Axis (HPOA) is the main biological axis regulating female / female neuroendocrine and reproduction. The hypothalamus plays a central role in the hormonal regulation of the female / female reproductive system. The effects of hormones released by the hypothalamus-pituitary system on ovarian follicles can cause a series of activities corresponding to the menstrual cycle. Studies have shown that some environmental pollutants can directly act on HPOA in the body, interfering with the synthesis and release of normal hormones and affecting the normal reproductive function of the ovaries.

[0003] Heavy metal cadmium (Cadmium, Cd) is easily converted into Cd 2+ Cadmium is released into the environment in the form of wastewater, waste gas and other environmental media. It is a highly toxic environmental pollutant to humans and animals. Cadmium in the environment mainly enters the human body through the respiratory tract and digestive tract, and is easily accumulated in the body's organs. Studies have found that pre-adolescents exposed to Cd 2+ It will reduce the number of neuronal cells and cause damage to the hypothalamus and pituitary tissue. 2+ It has estrogen-like effects and can affect the function of estrogen by interfering with the transcriptional activity of estrogen receptors. It is a potential pathogenic factor for estrogen-dependent diseases such as breast cancer and endometrial cancer, and may also affect ovarian function.

[0004] Procymidone (PCM) is an environmental endocrine disruptor (EEDs) commonly used to prevent and treat sclerotinia, gray mold and black spot of fruits, vegetables and crops. Studies by the European Food Safety Authority have shown that the dietary intake of PCM by residents in some areas exceeds the acceptable daily intake. Countries and regions such as China, the United States, the European Union, Japan, and Canada have set limits on the maximum residues of PCM in agricultural products. As an EEDs, PCM exhibits anti-androgenic properties both in vivo and in vitro, preventing androgens from binding to corresponding receptors, thereby inhibiting the expression of androgen-regulated genes, and ultimately causing abnormal development of male HPOA. In addition, PCM has a certain degree of fat solubility and may cause brain tissue damage through the blood-brain barrier.

[0005] PCM and Cd 2+These are two common environmental pollutants with EEDs properties. People usually ingest these two poisons through drinking water and eating. 2+ Both EDCA and PCM can pass through the blood-brain barrier and cause damage to the nervous system, especially the hypothalamus and pituitary gland. Therefore, it is of great practical significance to provide a method for preventing and treating environmental endocrine disruptors from damaging the hypothalamus-pituitary-ovarian axis. Summary of the invention

[0006] In view of this, the present invention provides the use of dyclonine hydrochloride in preventing hypothalamus-pituitary-ovarian axis damage in female mice. 2+ The potential mechanism of combined procymidone damage to the hypothalamus-pituitary-ovarian axis of mice, and based on this mechanism, a small molecule drug for preventing damage is provided, which is dyclonine hydrochloride, and the preparation method includes dissolving dyclonine hydrochloride in phosphate buffer, and then adjusting the pH value to about 7.4; the concentration of the small molecule drug for intraperitoneal injection is 10 mg / kg·bw / d. The preparation method of the small molecule drug of the present invention is simple, can effectively inhibit the RA signaling pathway and the NF-kB inflammatory pathway, has high safety, and can effectively protect the hypothalamus-pituitary-ovarian axis of female mice.

[0007] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0008] The present invention provides the use of dyclonine hydrochloride in any of the following items:

[0009] i) Preparation of drugs for restoring or improving reproductive capacity or fertility;

[0010] ii) preparing a drug for preventing or treating hypothalamus-pituitary-ovarian axis damage.

[0011] In some specific embodiments of the present invention, the preparation method of the drug comprises dissolving dyclonine hydrochloride in a phosphate buffer solution and adjusting the pH value to neutral to obtain the drug.

[0012] In some specific embodiments of the present invention, the neutrality in the above application is 7.0-7.6.

[0013] In some specific embodiments of the present invention, the concentration of the dyclonine hydrochloride in the phosphate buffer is 10 mg / mL.

[0014] In some specific embodiments of the present invention, the intraperitoneal injection dose of the drug is 5 mg / kg·bw / d, 6 mg / kg·bw / d, 7 mg / kg·bw / d, 8 mg / kg·bw / d, 9 mg / kg·bw / d or 10 mg / kg·bw / d.

[0015] In some specific embodiments of the present invention, the above-mentioned application of the hypothalamus-pituitary-ovarian axis injury caused by Cd 2+ Caused by combined use of carbendazim.

[0016] In some specific embodiments of the present invention, the above-mentioned use of restoring or improving reproductive capacity or fertility includes increasing the number of births.

[0017] In some specific embodiments of the present invention, the above-mentioned use for preventing or treating hypothalamus-pituitary-ovarian axis damage is achieved by inhibiting RA signaling pathway and NF-kB inflammatory pathway.

[0018] The present invention also provides a method for constructing a hypothalamus-pituitary-ovarian axis injury model based on Cd 2+ Constructed with carbendazim.

[0019] In some specific embodiments of the present invention, the hypothalamus-pituitary-ovarian axis injury model described in the above construction method is a hypothalamus-pituitary-ovarian axis injury model in female mice in vivo or a hypothalamus-pituitary-ovarian axis injury model in female mice in vitro;

[0020] The method for constructing a hypothalamus-pituitary-ovarian axis injury model in female mice comprises administering 0.0015 mg / L, 0.002 mg / L, 0.003 mg / L, 0.004 mg / L, 0.005 mg / L, 0.006 mg / L, 0.007 mg / L, 0.008 mg / L, 0.009 mg / L, 0.01 mg / L, 0.012 mg / L or 0.0135 mg / L Cd 2+ with 30 mg / kg / d, 40 mg / kg / d, 50 mg / kg / d, 60 mg / kg / d, or 70 mg / kg / d of procymidone;

[0021] The method for constructing an in vitro hypothalamus-pituitary-ovarian axis injury model of female mice comprises the steps of: subjecting the target organ to 2.8 μg / L, 3 μg / L, 4 μg / L, 5 μg / L, 6 μg / L, 7 μg / L, 8 μg / L, 9 μg / L, 10 μg / L, 11 μg / L, 12 μg / L, 13 μg / L, 14 μg / L, 15 μg / L, 16 μg / L, 17 μg / L, 18 μg / L, 19 μg / L, 20 μg / L, 21 μg / L, 22 μg / L, 23 μg / L, 24 μg / L or 25.2 μg / L Cd 2+ and 0.01mg / L, 0.02mg / L, 0.03mg / L, 0.04mg / L, 0.05mg / L, 0.63mg / L, 0.07mg / L, 0.08mg / L, 0.09mg / L or 0.1mg / L of procymidone;

[0022] The target organ is at least one of the hypothalamus, pituitary gland and ovary.

[0023] The present invention also provides the use of dyclonine hydrochloride in any of the following items:

[0024] i) Restoring or improving reproductive capacity or fertility;

[0025] ii) Prevent or treat damage to the hypothalamus-pituitary-ovarian axis.

[0026] The present invention provides an application of a DYC small molecule in preventing HPOA damage in female mice, which has a significant effect on the treatment of low-level Cd 2+ Combined with PCM, it has a preventive effect on HPOA damage in female mice.

[0027] In order to achieve the purpose of the present invention, the present invention provides an application of DYC in preventing HPOA damage in female mice, wherein the HPOA organs of female mice are the hypothalamus, pituitary gland and ovary of female mice.

[0028] Furthermore, the damage to HPOA in the female mice was Cd 2+ concentration and 1 / 2 of the no observed adverse effect level (NOAEL) dose of PCM.

[0029] Furthermore, the present invention uses DYC to prepare a small molecule drug for preventing EEDs from damaging HPOA in female mice.

[0030] Furthermore, the method for preparing the small molecule drug is as follows: dissolving DYC in a phosphate buffer and then adjusting the pH value to about 7.4. The concentration of DYC in the phosphate buffer is 10 mg / mL.

[0031] Furthermore, the concentration of the small molecule drug for intraperitoneal injection is 5 to 10 mg / kg·bw / d. Preferably, the concentration of the small molecule drug for intraperitoneal injection is 10 mg / kg·bw / d.

[0032] The present invention uses small molecule drugs to antagonize low levels of Cd 2+ Combined with PCM to protect HPOA in female mice, that is, to prepare small molecule drugs to antagonize low levels of Cd 2+ In the model of protecting HPOA of female mice combined with PCM, 10 mg / kg·bw / d of small molecule drugs were injected into the peritoneal cavity of female mice, so that they could play a role in HPOA of female mice, and finally produce organ protection or organ damage repair effect.

[0033] The present invention also provides a method for preparing an EEDs-damaged HPOA animal model, wherein a mixed solution of PCM and corn oil at about 1 / 2 NOAEL is administered to mice, and Cd 2+ Concentration water or ultrapure water was provided to mice for free drinking.

[0034] The present invention also provides a method for verifying the mechanism of EEDs damaging HPOA. 2+ PCM at a concentration of 1 / 2 of the NOAEL level can cause damage to HPOA in adolescent female mice. The expression of follicle-stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E2), progesterone (P), Adh1b, Rdh 10, Aldh2, Cyp26a1, Nf-kb, Nlrp3, IL-1β, IL-18, and Caspase-1 proteins can qualitatively (or semi-quantitatively) evaluate the degree of HPOA damage.

[0035] The present invention also provides an in vitro culture method for female mouse HPOA.

[0036] In vitro culture method of female mouse hypothalamus, pituitary and ovary: under a sterile environment, remove the mouse hypothalamus, pituitary and bilateral ovaries, immediately rinse three times with sterile phosphate buffered saline (PBS, pH 7.4), and then cut the hypothalamus, pituitary and ovaries into 1-2 mm pieces with a lancet under a stereomicroscope. 3 The tissue blocks of hypothalamus, pituitary and ovary were randomly inoculated into the culture medium of each well, about 2-3 blocks per well. The cells were cultured in a 5% CO2, 95% air incubator at 37°C.

[0037] The main components of the culture medium are: DMEM / F12 culture medium, 10% fetal bovine serum, 1% penicillin-streptomycin, and 1% ascorbic acid.

[0038] In the present invention, the in vitro culture of HPOA of female mice is preferentially performed by dropping low melting point agarose gel into the wells of a 24-well culture plate to solidify into "columns", and then each group is cultured and added to the culture wells respectively. The culture model is processed as shown in Figure 1 Schematic diagram of an in vitro culture model of HPOA. In addition, in the present invention, the pH value of the culture medium containing DYC is adjusted to 7.35-7.45 using sodium hydroxide or sodium carbonate to alkaline the solution and balance the damage of acidic substances to tissues.

[0039] The present invention also provides a method for collecting and detecting HPOA tissue in adolescent mice. That is, after the mice are anesthetized, blood is collected from the abdominal aorta for testing, and then the brain tissue and ovary are quickly collected after the mice are killed by cervical dislocation; the mouse blood (or organ culture medium) is centrifuged and the supernatant is collected for sex hormone detection; the mouse HPOA is subjected to histopathological observation, and the key proteins in the HPOA tissue are detected by western blot.

[0040] The present invention has the following effects:

[0041] 1. This paper constructs an EEDs-damaged female mouse HPOA model and conducts basic research to preliminarily explore the possible mechanism of EEDs-damaged mouse HPOA. 2+ The extent to which PCM can cause damage to HPOA in adolescent mice can be determined, and intervention drugs can be developed accordingly to achieve the best preventive and therapeutic effects; small molecule drugs are used to inhibit the RA signaling pathway and the NLRP3 / NF-kB pathway, and play a preventive and therapeutic role, ultimately producing HPOA protection or damage repair effects;

[0042] 2. The present invention is supported by basic experimental data, and the drug has high effectiveness and safety. The present invention not only verifies the effect of small molecule drugs for alleviating HPOA damage, but also further explores the specific effects of different drug doses on HPOA in injured female mice. Therefore, the dose-response relationship of the drug effect can be clarified, which is conducive to guiding practical applications. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art are briefly introduced below.

[0044] Figure 1 Schematic diagram of HPOA in vitro culture model;

[0045] Figure 2 Showing low level of Cd 2+ Pathological sections of hypothalamic tissue damage in female adolescent mice caused by combined PCM;

[0046] Figure 3 Showing low level of Cd 2+ Nissl staining of hypothalamic tissue damage in female adolescent mice induced by combined PCM;

[0047] Figure 4 Showing low level of Cd 2+ Electrophoretic band diagram of differential expression of Adh1b, Rdh10, Aldh2, and Cyp26a1-related proteins in the hypothalamus of female adolescent mice induced by combined PCM;

[0048] Figure 5 Showing low level of Cd2+ Electrophoretic band diagram of differential expression of Nf-kb, Nlrp3, IL-1β, IL-18, and Caspase-1 related proteins in the hypothalamus of female adolescent mice induced by combined PCM;

[0049] Figure 6 Showing low level of Cd 2+ Pathological sections of pituitary tissue damage in female adolescent mice caused by combined PCM;

[0050] Figure 7 Showing low level of Cd 2+ Nissl staining of pituitary tissue damage in female adolescent mice induced by combined PCM;

[0051] Figure 8 Showing low level of Cd 2+ Electrophoretic band diagram of differential expression of Adh1b, Rdh10, Aldh2, and Cyp26a1 related proteins in the pituitary of female adolescent mice induced by combined PCM;

[0052] Fig. 9 Showing low level of Cd 2+ Electrophoretic band diagram of differential expression of pituitary Nf-kb, Nlrp3, IL-1β, IL-18, and Caspase-1 related proteins in female adolescent mice induced by combined PCM;

[0053] Fig.10 Showing low level of Cd 2+ Pathological sections of ovarian tissue damage in female adolescent mice caused by combined PCM;

[0054] Fig.11 Showing low level of Cd 2+ Immunofluorescence images of ovarian tissue damage in female adolescent mice induced by combined PCM;

[0055] Fig.12 Showing low level of Cd 2+ Electrophoretic band diagram of differential expression of Adh1b, Rdh10, Aldh2, and Cyp26a1-related proteins in the ovaries of female adolescent mice induced by combined PCM;

[0056] Fig.13 Showing low level of Cd 2+ Electrophoretic band diagram of differential expression of Nf-kb, Nlrp3, IL-1β, IL-18, and Caspase-1 related proteins in the ovaries of female adolescent mice induced by combined PCM;

[0057] Fig.14 Showing low level of Cd 2+ Pathological sections of hypothalamus damage in female rats cultured in vitro caused by combined PCM;

[0058] Fig.15 Showing low level of Cd 2+ Nissl staining of the damage of hypothalamic tissue of female rats cultured in vitro caused by combined PCM;

[0059] Fig.16 Showing low level of Cd 2+ Electrophoretic band diagram of differential expression of Adh1b, Rdh10, Aldh2, and Cyp26a1 related proteins in the hypothalamus of female mice cultured in vitro induced by PCM;

[0060] Fig.17 Showing low level of Cd 2+ Electrophoretic band diagram of differential expression of Nf-kb, Nlrp3, IL-1β, IL-18, and Caspase-1 related proteins in the hypothalamus of female mice cultured in vitro induced by PCM;

[0061] Fig.18 Showing low level of Cd 2+ Pathological section of pituitary tissue damage of female rats cultured in vitro caused by combined PCM;

[0062] Fig.19 Showing low level of Cd 2+ Nissl staining of pituitary tissue damage in vitro cultured female mice caused by combined PCM;

[0063] Fig. 20 Showing low level of Cd 2+ Electrophoretic band diagram of differential expression of Adh1b, Rdh10, Aldh2, and Cyp26a1 related proteins in the pituitary of female mice cultured in vitro induced by combined PCM;

[0064] Fig.21 Showing low level of Cd 2+ Electrophoretic band diagram of differential expression of Nf-kb, Nlrp3, IL-1β, IL-18, and Caspase-1 related proteins in the pituitary of female mice cultured in vitro induced by PCM;

[0065] Fig. 22 Showing low level of Cd 2+ Pathological section of the damage of ovarian tissue of female mice cultured in vitro caused by combined PCM;

[0066] Fig.23 Showing low level of Cd 2+ Electrophoretic band diagram of differential expression of Adh1b, Rdh10, Aldh2, and Cyp26a1 related proteins in female mouse ovaries cultured in vitro induced by combined PCM;

[0067] Fig.24 Showing low level of Cd 2+Electrophoretic band diagram of the differential expression of Nf-kb, Nlrp3, IL-1β, IL-18, and Caspase-1 related proteins in the in vitro cultured female mouse ovaries induced by PCM;

[0068] Fig.25 DYC antagonizes low-level Cd 2+ Pathological sections of the hypothalamus of female adolescent mice protected by combined PCM;

[0069] Fig.26 DYC antagonizes low-level Cd 2+ Nissl staining of the hypothalamus of female adolescent mice protected by combined PCM;

[0070] Fig. 27 DYC antagonizes low-level Cd 2+ The differential expression bar graph of genes related to Adh1b, Rdh10, Aldh2, and Cyp26a1 in the hypothalamus of female adolescent mice protected by combined PCM;

[0071] Fig.28 DYC antagonizes low-level Cd 2+ The differential expression bar graph of Nf-kb, Nlrp3, IL-1β, IL-18, and Caspase-1 related genes in the hypothalamus of female adolescent mice protected by combined PCM;

[0072] Fig.29 DYC antagonizes low-level Cd 2+ Pathological sections of the pituitary gland of female adolescent mice protected by combined PCM;

[0073] Fig.30 DYC antagonizes low-level Cd 2+ Nissl staining of pituitary gland of female adolescent mice protected by combined PCM;

[0074] Fig.31 DYC antagonizes low-level Cd 2+ The differential expression bar graph of Adh1b, Rdh10, Aldh2, and Cyp26a1 related genes in the pituitary of female adolescent mice with combined PCM;

[0075] Fig.32 DYC antagonizes low-level Cd 2+ The differential expression bar graph of Nf-kb, Nlrp3, IL-1β, IL-18, and Caspase-1 related genes in the pituitary of female adolescent mice combined with PCM;

[0076] Fig.33 DYC antagonizes low-level Cd 2+ Pathological sections of the ovaries of female adolescent mice protected by combined PCM;

[0077] Fig.34 DYC antagonizes low-level Cd 2+ The differential expression bar graph of Adh1b, Rdh10, Aldh2, and Cyp26a1 related genes in the ovaries of female adolescent mice with combined PCM;

[0078] Fig.35 DYC antagonizes low-level Cd 2+ The differential expression bar graph of Nf-kb, Nlrp3, IL-1β, IL-18, and Caspase-1 related genes in the ovaries of female adolescent mice treated with PCM;

[0079] Fig.36 Shows the pathological sections of the hypothalamus of female adolescent mice cultured in vitro after DYC intervention;

[0080] Fig.37 Shows the Nissl staining of the hypothalamus of female adolescent mice cultured in vitro after DYC intervention;

[0081] Fig.38 The electrophoretic band diagram shows the differential expression of Adh1b, Rdh10, Aldh2, and Cyp26a1 related proteins in the hypothalamus of female adolescent mice cultured in vitro after DYC intervention;

[0082] Fig.39 The electrophoretic band diagram shows the differential expression of Nf-kb, Nlrp3, IL-1β, IL-18, and Caspase-1 related proteins in the hypothalamus of female adolescent mice cultured in vitro after DYC intervention;

[0083] Fig.40 Shows the pathological sections of pituitary glands of female adolescent mice cultured in vitro after DYC intervention;

[0084] Fig.41 Shows the Nissl staining of the pituitary of female adolescent mice cultured in vitro after DYC intervention;

[0085] Fig.42 The electrophoretic band diagram shows the differential expression of Adh1b, Rdh10, Aldh2, and Cyp26a1 related proteins in the pituitary of female adolescent mice cultured in vitro after DYC intervention;

[0086] Fig.43 The electrophoretic band diagram shows the differential expression of Nf-kb, Nlrp3, IL-1β, IL-18, and Caspase-1 related proteins in the pituitary of female adolescent mice cultured in vitro after DYC intervention;

[0087] Fig.44 Shows the pathological sections of the ovaries of female adolescent mice cultured in vitro after DYC intervention;

[0088] Fig.45 The electrophoretic band diagram shows the differential expression of Adh1b, Rdh10, Aldh2, and Cyp26a1 related proteins in the ovaries of female adolescent mice cultured in vitro after DYC intervention;

[0089] Fig.46 The electrophoretic band diagram shows the differential expression of Nf-kb, Nlrp3, IL-1β, IL-18, and Caspase-1 related proteins in the ovaries of female adolescent mice cultured in vitro after DYC intervention;

[0090] in, Figure 2 , Figure 3 , Figure 4 , Figure 5 , Figure 6 , Figure 7 , Figure 8 , Fig. 9 , Fig.10 , Fig.11 , Fig.12 , Fig.13 C = control group, Cd 2+ =0.0045mg / L Cd 2+ , PCM=50mg / kg / d PCM, L+PCM=0.0015mg / L Cd 2+ +50mg / kg / d PCM, M+PCM=0.0045mg / L Cd 2+ +50mg / kg / d PCM, H+PCM=0.0135mg / L Cd 2+ +50mg / kg / d PCM;

[0091] Fig.14 , Fig.15 , Fig.16 , Fig.17 , Fig.18 , Fig.19 , Fig. 20 , Fig.21 , Fig. 22 , Fig.23 , Fig.24 C = control group, Cd 2+ =8.4μg / L Cd 2+ , PCM=0.63mg / L PCM, L+PCM=2.8μg / L Cd 2+ +0.63mg / L PCM, M+PCM=8.4μg / L Cd 2+ +0.63mg / L PCM, H+PCM=25.2μg / L Cd 2+ +0.63mg / L PCM;

[0092] Fig.25, Fig.26 , Fig. 27 , Fig.28 , Fig.29 , Fig.30 , Fig.31 , Fig.32 , Fig.33 , Fig.34 , Fig.35 NC = negative control group, PC = 0.0135 mg / L Cd 2+ +50mg / kg / d PCM, 7 days, M = simultaneous intragastric administration of low-level Cd 2+ Combined PCM (0.0135mg / L Cd 2+ +50mg / kg / d PCM) and intraperitoneal injection of DYC (10mg / kg bw / d) for 7 consecutive days, B = oral administration of low-level Cd 2+ Combined PCM (0.0135mg / L Cd 2+ +50mg / kg / d PCM) intraperitoneally injected with DYC (10mg / kg bw / d) 24 hours before for 7 consecutive days. A = low level Cd 2+ Combined PCM (0.0135mg / L Cd 2+ +50mg / kg / d PCM) for 7 days, followed by intraperitoneal injection of DYC (10mg / kg·bw / d) for 7 days; the results are mean ± SD, n = 8, ANOVA, t test; *P < 0.05 indicates that the difference between each group and the NC group is statistically significant; #P < 0.05 indicates that the difference between each intervention group and the PC group is statistically significant;

[0093] Fig.36 , Fig.37 , Fig.38 , Fig.39 , Fig.40 , Fig.41 , Fig.42 , Fig.43 , Fig.44 , Fig.45 , Fig.46 C = control group, PC = 25.2 μg / L Cd 2+ +0.63mg / L PCM, L=25.2μg / L Cd 2+ +0.63mg / L PCM+8.15μg / L DYC, M=25.2μg / L Cd 2+ +0.63mg / L PCM+16.29μg / L DYC, H=25.2μg / L Cd 2+ +0.63mg / L PCM+32.59μg / L DYC. DETAILED DESCRIPTION

[0094] The present invention discloses the use of dyclonine hydrochloride in preventing hypothalamus-pituitary-ovarian axis damage in female mice. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It should be particularly noted that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.

[0095] The study of this application found that low levels of Cd 2+ And / or PCM can aggravate HPOA tissue damage by affecting the retinoic acid (RA) signaling pathway and NLRP3 / NF-kB inflammatory pathway in HPOA of adolescent mice. Based on this, dyclonine hydrochloride (DYC) was used to maintain the homeostasis of the above proteins to prevent and treat HPOA damage in mice.

[0096] Unless otherwise specified, the raw materials, reagents, consumables and instruments involved in the present invention are all common commercial products and can be purchased from the market.

[0097] The present invention will be further described below in conjunction with the embodiments.

[0098] Example 1: Low Level Cd 2+ Combined PCM induces HPOA damage in adolescent female mice

[0099] (1) Low level Cd 2+ Establishment of HPOA injury model in adolescent female mice induced by combined PCM

[0100] ① HPOA injury model in female mice:

[0101] According to the Cd 2+ Female mice were exposed to a concentration of 0.005 mg / L combined with 1 / 2 the NOAEL dose of procymidone (50 mg / kg·bw / d).

[0102] PCM solution was obtained by suspending PCM in pure corn oil. The solution was prepared immediately before use. The volume of gavage was adjusted according to the weight of female mice. The gavage was performed once a day for 21 consecutive days. At the same time, Cd 2+ Concentration water or ultrapure water was provided to mice for free drinking.

[0103] 6 sets of low-level Cd 2+ Combined PCM dosage is as follows:

[0104] Control group: pure corn oil 0 mg / kg·d;

[0105] Cd only 2+ Exposure group: corn oil + 0.0045mg / L Cd 2+ ;

[0106] PCM group: 50 mg / kg / d PCM;

[0107] Low dose Cd 2+ +PCM group: 0.0015mg / L Cd 2+ +50mg / kg / d PCM;

[0108] Medium dose Cd 2+ +PCM group: 0.0045mg / L Cd 2+ +50mg / kg / d PCM;

[0109] High dose Cd 2+ +PCM group: 0.0135mg / L Cd 2+ +50mg / kg / d PCM;

[0110] During the experiment, the food intake and mental state of female mice in each group were observed daily.

[0111] ② Female mouse in vitro HPOA injury model:

[0112] The cultured tissues were randomly divided into 6 groups:

[0113] Cd only 2+ Poisoning group: acetone + 8.4μg / L Cd 2+ ;

[0114] PCM group: 0.63mg / L PCM;

[0115] Low dose Cd 2+ +PCM group: 2.8μg / L Cd 2+ +0.63mg / L PCM;

[0116] Medium dose Cd 2+ +PCM group: 8.4 μg / L Cd 2+ +0.63mg / L PCM;

[0117] High dose Cd 2+ +PCM group: 25.2μg / L Cd 2+ +0.63mg / L PCM;

[0118] The control group was given an equal volume of acetone;

[0119] Anhydrous cadmium chloride was dissolved in ultrapure water, PCM was dissolved in acetone, and the final concentration of all experimental and control incubation solutions was 0.1% acetone, and then cultured according to the culture method of hypothalamus, pituitary and ovary.

[0120] (2) Low level Cd 2+ Detection of FSH, LH, E2 and P in HPOA damage of adolescent female mice induced by combined PCM

[0121] From the above low level Cd 2+ Blood was collected from the abdominal aorta of female mice in the HPOA injury model of adolescent female mice induced by PCM and centrifuged (speed 3000r / min, centrifugal radius 160mm, centrifugal time 10min), and the supernatant was taken. According to the instructions of each hormone ELISA detection kit, after adding the relevant detection solution, the absorbance value of the sample was determined using an automatic enzyme marker, and converted into sex hormone content according to the standard curve.

[0122] (3) Low level Cd 2+ Tissue collection of HPOA damage in adolescent female mice induced by combined PCM

[0123] Female mice were anesthetized with ether and blood was collected from the abdominal aorta. HPOA organs (hypothalamus, pituitary gland and ovary) were removed by laparotomy. One part was used for volume measurement and mass weighing, and placed in 4% paraformaldehyde fixative for pathological section preparation; another part was placed in Ep tubes containing RIPA lysis solution for protein detection.

[0124] (4) Low level Cd 2+ Histopathological observation of HPOA damage induced by PCM in adolescent female mice

[0125] The fixed HPOA organs were graded and dehydrated from low to high concentrations of ethanol, embedded in paraffin, and then serially sectioned at 5 μm intervals, stained with hematoxylin-eosin (HE), and sealed. One slice was taken every five slices, and five fields of view were randomly selected for observation in each slice.

[0126] After drying, the hypothalamus and pituitary tissue sections were dewaxed with xylene and ethanol gradient, washed with distilled water to remove the ethanol, and then stained in Nissl staining solution for 10 minutes, washed with distilled water twice, dehydrated in 95% ethanol twice, each time for 2 minutes, and then transparentized in xylene twice, each time for 5 minutes, and sealed. Then, the sections were observed and photographed under an optical microscope.

[0127] (5) Low level Cd 2+ Detection of key proteins in the HPOA damage model of adolescent female mice induced by combined PCM

[0128] The organ specimen tissue of HPOA was placed in RIPA lysis buffer, homogenized at 4°C, and the supernatant was taken as the total protein solution. The protein was then quantified using the bicinchoninic acid method, and finally 0.1% phenylmethylsulfonyl fluoride was added and frozen.

[0129] The total protein was added to the loading buffer and boiled for 5 minutes for denaturation, and 10% SDS-PAGE gel was used for denaturation electrophoresis separation, with a loading amount of 10 μg / well and electrophoresis parameters: concentrated gel 80V, 20min; separation gel 120V, 90min. Then, it was transferred to polyvinylidene fluoride (PVDF) membrane at 100V, 120min. Block with 5% skim milk powder for 1 h; dilute the primary antibody with Western diluent (anti-Aldh2 monoclonal antibody 1:1000, anti-Cyp26a1 monoclonal antibody 1:1000, anti-Adh1b, monoclonal antibody 1:1000, anti-Rdh10 monoclonal antibody 1:1000, anti-Nlrp3 monoclonal antibody 1:1000, anti-Nf-kb monoclonal antibody 1:1000, anti-IL-1β monoclonal antibody 1:1000, anti-IL-18 monoclonal antibody 1:1000, anti-Caspase-1 monoclonal antibody 1:1000, β-actin monoclonal antibody 1:2000), incubate at 4°C overnight; wash the membrane 3 times with 1×TBST, 10 min / time. Add the secondary antibody diluted in TBST (anti-rabbit HRP-IgG 1:8000) and incubate on a shaker at room temperature for 1 h; wash the membrane 3 times with 1× TBST, 10 min each time.

[0130] A chemiluminescence imaging system was used for photographing and development.

[0131] (6) Low level Cd 2+ Immunofluorescence detection of the ovarian damage model of adolescent female mice induced by PCM

[0132] Mouse ovarian tissue sections were dewaxed and hydrated with xylene and ethanol gradients, and endogenous peroxidase was eliminated with 3% H2O2. Antigen retrieval was performed with sodium citrate buffer at pH = 6.0 for 15 minutes, blocked with 3% BSA at room temperature for 1 hour, washed with PBS 3 times, and incubated with ALDH2 polyclonal antibody diluted 1:100 as primary antibody at 4°C overnight. Then, after cooling at room temperature for 1 hour, washed with PBST 4 times, incubated with fluorescent secondary antibody 1:250 at room temperature in the dark for 1 hour, washed with PBST 3 times, and stained with DAPI staining solution for 5 minutes. Finally, fluorescent antifade agent was added to the sections to seal the sections, and observed and photographed with a LEICA fluorescence microscope.

[0133] Experimental results:

[0134] In vitro and in vivo experiments, with low levels of Cd2+ With the increase of PCM dose, the levels of FSH, LH, E2, and P decreased (see Table 1 and Table 2). The number of neurons in the hypothalamus decreased, the nuclei shrank, the Nissl bodies decreased, and the cell bodies shrank and deformed (such as Figure 2 , Figure 3 , Fig.14 , Fig.15 The number of nerve cells in the pituitary gland decreases, the number of Nissl bodies decreases, the cell density decreases, and the cells become pyknotic and deformed (such as Figure 6 , Figure 7 , Fig.18 , Fig.19 The number of follicles at all levels in the ovaries decreased (see Table 3, Table 4, Table 5, Table 6, Fig.10 , Fig. 22 ), the above results suggest that low levels of Cd 2+ Combined PCM was involved in the growth and development of adolescent mice, leading to weight loss in adulthood, dose-dependent decreases in FSH, LH, E2, and P levels, and pathological changes in the hypothalamus, pituitary, and ovaries.

[0135] Table 1: FSH, LH, E2, and P concentrations in serum / culture medium before intervention

[0136]

[0137] Table 2: FSH, LH, E2, and P concentrations in serum / culture medium after intervention

[0138]

[0139] (Note: The results in Table 1 and Table 2 are mean ± standard deviation, n = 8, ANOVA, t test; *P < 0.05 indicates that the difference between each dose group and the control group is statistically significant; #P < 0.05 indicates that the difference between the low, medium and high dose groups and the PCM group is statistically significant.

[0140] There is statistical significance; ΔP<0.05 indicates that the medium dose group is significantly higher than Cd 2+ The difference was statistically significant between the two groups)

[0141] Table 3: Follicle counts in ovarian tissue of mice before intervention

[0142]

[0143] (Note: Ovarian tissue follicle count n = 8, )

[0144] Table 4: Follicle counts in ovarian tissue of mice after intervention

[0145]

[0146] (Note: Ovarian tissue follicle count n = 8, )

[0147] Table 5: Follicle counts in ovarian tissue culture experiments before intervention

[0148]

[0149]

[0150] (Note: Ovarian tissue follicle count n = 8, )

[0151] Table 6: Follicle counts in ovarian tissue culture experiments after intervention

[0152]

[0153] (Note: Ovarian tissue follicle count n = 8, )

[0154] At the same time, if Figure 4 , Figure 5 , Figure 8 , Fig. 9 , Fig.12 , Fig.13 , Fig.16 , Fig.17 , Fig. 20 , Fig.21 , Fig.23 , Fig.24 Protein results showed that low levels of Cd 2+ Combined with PCM, it activates the RA signaling pathway and the NF-kB inflammatory pathway. Fig.11 The results of immunofluorescence showed that ALDH2 was localized in the cytoplasm in the ovary, and the trend was consistent with the WB results of ALDH2. Compared with the control group, the ALDH2 fluorescence intensity in the PCM, low, medium, and high dose groups was significantly enhanced. 2+ Combined PCM participated in the dose-dependent injury of HPOA in vivo and in vitro.

[0155] Example 2: DYC antagonizes low levels of Cd 2+ Combined with PCM to protect HPOA in female mice

[0156] (1) DYC antagonizes low-level Cd 2+ Model establishment of combined PCM to protect HPOA in female mice

[0157] ① Experimental grouping of female mice: After one week of adaptive feeding, the female mice were randomly divided into 5 groups according to their body weight:

[0158] Positive control group (PC): oral administration of low-level Cd 2+ Combined PCM 0.0135mg / L Cd2+ +50 mg / kg / dPCM for 7 consecutive days;

[0159] Negative control group (NC): Orally administered with an equal volume of corn oil for 7 days;

[0160] Group M: low-level Cd was given by gavage simultaneously 2+ Combined PCM (0.0135mg / L Cd 2+ +50 mg / kg / d PCM) and intraperitoneal injection of DYC (10 mg / kg·bw / d) for 7 consecutive days;

[0161] Group B: Intragastric administration of low-level Cd 2+ Combined PCM (0.0135mg / L Cd 2+ +50 mg / kg / d PCM) by intraperitoneal injection of DYC (10 mg / kg bw / d) 24 h before for 7 consecutive days;

[0162] Group A: Intragastric administration of low level Cd 2+ Combined PCM (0.0135mg / L Cd 2+ + 50 mg / kg / d PCM) for 7 days, and then DYC (10 mg / kg bw / d) was injected intraperitoneally for 7 days.

[0163] ② Grouping of in vitro cultured tissues:

[0164] Low level Cd 2+ The experimental results of PCM-induced HPOA damage in vitro showed that 25.2 μg / L Cd 2+ Combined with 0.63 mg / L PCM, it can cause obvious changes in molecular biological indicators such as histology, RA signaling pathway and NLRP3 / NF-kB inflammatory pathway in the hypothalamus, pituitary and ovary cultured in vitro. Therefore, 25.2 μg / L Cd 2+ The RA signaling pathway and NLRP3 / NF-kB inflammatory pathway activation experiments were performed in combination with 0.63 mg / L PCM-induced HPOA injury model in vitro. The experiment was divided into 5 groups:

[0165] Positive control group (PC): 25.2μg / L Cd 2+ +0.63mg / L PCM;

[0166] Control group (C): given an equal volume (0.1%) of acetone;

[0167] Low dose (L) group: 25.2 μg / L Cd 2+ +0.63mg / L PCM+8.15μg / L DYC;

[0168] Medium dose (M) group: 25.2 μg / L Cd2+ +0.63mg / L PCM+16.29μg / L DYC;

[0169] High dose (H) group: 25.2 μg / L Cd 2+ +0.63mg / L PCM+32.59μg / L DYC;

[0170] (2) DYC antagonizes low-level Cd 2+ The detection of FSH, LH, E2, and P in the HPOA of adolescent female mice protected by PCM is the same as step (2) in Example 1, and specific reference is made to Example 1.

[0171] (3) DYC antagonizes low-level Cd 2+ The tissue collection of HPOA of adolescent female mice protected by PCM is the same as step (3) in Example 1, and specific reference is made to Example 1.

[0172] (4) DYC antagonizes low-level Cd 2+ The histopathological observation of the protection of HPOA in adolescent female mice by PCM is the same as step (4) in Example 1, and specific reference is made to Example 1.

[0173] (5) DYC antagonizes low-level Cd 2+ Total RNA extraction and real-time fluorescence quantitative PCR of tissues for the protection of HPOA in adolescent female mice by PCM

[0174] The reproductive organs frozen at -80℃ were quickly cut into pieces on ice, placed in a centrifuge tube containing 1mL TRIzol, homogenized at 4℃, and the total RNA of the sample was extracted according to the instructions of the kit. The RNA extracted from the tissue was dissolved in RNase-free water, and 1μg was taken for reverse transcription to synthesize cDNA. The reaction system and conditions were specifically operated according to the instructions.

[0175] After obtaining cDNA, an amplification reaction was performed, and the reaction system was as follows: SYBR Green, 2.5 μL; cDNA, 0.5 μL; forward primer, 0.3 μL; reverse primer, 0.3 μL; RNase-free water, 6.4 μL.

[0176] The reaction conditions of the amplification reaction were set as follows: 95°C for 10 min, 95°C for 15 s, 60°C for 1 min, and 40 cycles. The CT values ​​of the target gene in the experimental group and the control group were subtracted from the corresponding CT values ​​of the internal reference gene to obtain ΔCT, and then the ΔCT of the dose group was subtracted from the corresponding ΔCT of the control group to obtain ΔΔCT. After normalization, the amount of the target gene relative to the internal reference gene was Y=2 -ΔΔCt .

[0177] Experimental results:

[0178] In the in vitro and in vivo experiments, with the increase of DYC dose, the pathological damage in the hypothalamus, pituitary and ovarian tissue sections of the DYC group gradually decreased, and multiple follicles at different developmental stages were observed in the ovaries (see Table 3, Table 4, Table 5, Table 6, Fig.33 , Fig.44 ), the number of nerve cells in the hypothalamus and pituitary gland increases, and the cell density increases. (See Fig.25 , Fig.26 , Fig.29 , Fig.30 , Fig.36 , Fig.37 , Fig.40 , Fig.41 ), and gradually approached the control group. At the same time, the FSH, LH of the pituitary gland and the E2, P of the ovary in the dyclonine hydrochloride group increased (see Table 1, Table 2).

[0179] like Fig.38 , Fig.39 , Fig.42 , Fig.43 , Fig.45 , Fig.46 In vitro experiments showed that DYC inhibited the RA signaling pathway and NF-kB inflammatory pathway to reduce the level of Cd 2+ Combined with PCM, it has a protective effect on HPOA damage, among which the effect of group H is the greatest. Fig. 27 , Fig.28 , Fig.31 , Fig.32 , Fig.34 , Fig.35 As shown in the in vivo experiment, the M group was sensitive to low levels of Cd 2+ The protective effect of DYC combined with PCM on HPOA damage in mice was the best, followed by group B, and group A had the worst effect, indicating that DYC has a protective effect on low-level Cd 2+ Combined with PCM, it plays a preventive role in HPOA damage.

[0180] In summary, the higher the dose of DYC is, or when it is given simultaneously, the more effective it is for treating low levels of Cd 2+ The protective effect of combined PCM on HPOA damage is better.

[0181] Example 3: Low Level Cd 2+ Reproduction experiment after combined PCM or DYC exposure

[0182] In view of the M group in the model of Example 2 (simultaneously given low level Cd 2+ Combined PCM and DYC group) 2+The protective effect of PCM on HPOA damage in mice was the best. Therefore, female mice and normal male mice were randomly selected from the negative control group, positive control group and M group of the model in Example 2 for breeding experiments. The offspring mice born by pregnant mice were used as observation objects. The number of fetuses was calculated to evaluate the protective effect of low-level Cd 2+ Effects of combined PCM exposure on HPOA function in mice and DYC antagonism against low levels of Cd 2+ The effect of combined PCM on protecting HPOA function in adolescent mice.

[0183] Mouse experimental groups:

[0184] ① Female mice in the negative control group were caged together with male mice in the negative control group;

[0185] ②The female mice in the positive control group and the male mice in the negative control group were placed in the same cage;

[0186] ③The female mice in group M (DYC intervention group) and the male mice in the negative control group were placed in the same cage.

[0187] Each group consisted of 20 female mice and 10 male mice, which were marked with ear tags. The mice were caged together at 22:00 at night, and the male mice were taken out at 8:00 the next day. After observing the vaginal plugs of the female mice after caged together to confirm fertilization, they were placed in new breeding cages and raised separately to complete the first generation of breeding experiments. When the pups were born, the number and gender of the pups of each pregnant mouse were counted.

[0188] Experimental results:

[0189] As shown in Table 7, the number of fetuses in each group was calculated and it was found that low levels of Cd 2+ The litter size in the combined PCM group was significantly lower than that in the control group, and the litter size in the DYC intervention group was significantly higher than that in the low-level Cd 2+ Combined with PCM group, indicating that mice were exposed to low levels of Cd during adolescence 2+ Combined with PCM, although the appearance of both parent and offspring mice was normal, it could cause damage to their HPOA function and reduced reproductive capacity, while DYC could effectively protect adolescent mice from low levels of Cd 2+ HPOA system damage caused by combined PCM.

[0190] Table 7: Baseline data of litters born in the breeding trial

[0191]

[0192] Experimental conclusion:

[0193] From the above results, it can be seen that DYC can prevent low-level Cd 2+ Combined PCM-induced HPOA system damage in adolescent mice.

[0194] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Use of dyclonine hydrochloride in any of the following: i) preparing drugs for preventing or treating hypothalamus-pituitary-ovarian axis damage; ii) Preparation of drugs for restoring or improving reproductive capacity or fertility.

2. The use according to claim 1, characterized in that The preparation method of the drug comprises dissolving dyclonine hydrochloride in a phosphate buffer solution and adjusting the pH value to 7.4 to obtain the drug.

3. The use according to claim 2, characterized in that The concentration of the dyclonine hydrochloride in the phosphate buffer is 10 mg / mL.

4. The use according to claim 1, characterized in that The intraperitoneal injection dosage of the drug is 5 to 10 mg / kg·bw / d.

5. The use according to claim 4, characterized in that The intraperitoneal injection dose of the drug is 10 mg / kg·bw / d.

6. The use according to claim 1, characterized in that The hypothalamus-pituitary-ovarian axis damage caused by Cd 2+ Caused by combined use of carbendazim.

7. The use according to claim 1, characterized in that The prevention or treatment of hypothalamus-pituitary-ovarian axis damage is achieved by inhibiting the RA signaling pathway and the NF-kB inflammatory pathway.

8. The use according to claim 1, characterized in that Restoring or increasing reproductive capacity or fertility includes increasing the number of births.

9. A method for constructing a hypothalamus-pituitary-ovarian axis injury model, characterized in that: Based on Cd 2+ Constructed with carbendazim.

10. The construction method according to claim 9, characterized in that: The hypothalamus-pituitary-ovarian axis injury model is a hypothalamus-pituitary-ovarian axis injury model in female mice in vivo or a hypothalamus-pituitary-ovarian axis injury model in female mice in vitro; The method for constructing a hypothalamus-pituitary-ovarian axis injury model in female mice comprises administering 0.0015-0.0135 mg / L Cd 2+ with 50mg / kg / d of procymidone; The method for constructing an in vitro hypothalamus-pituitary-ovarian axis injury model of female mice comprises: exposing the target organ to 2.8-25.2 μg / L Cd 2+ and 0.63 mg / L procymidone exposure; The target organ is at least one of the hypothalamus, pituitary gland and ovary.

Citation Information

Patent Citations

  • Preparation for increasing erection rigidity and prolonging intercourse endurance and condom containing the same

    CN101167879A

  • Vaginally administered anti-dysrhythmic agents for treating pelvic pain and infertility

    CN101327326A

  • Application of cyanidin-3-O-glucoside in preparation of drugs for treating and / or preventing hormonal disorder diseases

    CN109999050A

  • Application of 4-phenylbutyric acid in prevention of female mouse reproductive organ injury

    CN114948921A

  • Application of TT-10 in preparation of medicine for preventing and / or treating reproductive organ injury

    CN116832035A